NCT06582108View on ClinicalTrials.gov

UNDERSTANDING the RAREST GYNECOLOGICAL CANCERS: a MULTI -OMICS PLATFORM for IMPROVED PATIENTS MANAGEMENT

Not yet recruitingOBSERVATIONAL

Enrollment

190

Participants

Timeline

Start Date

September 15, 2024

Primary Completion Date

September 15, 2026

Study Completion Date

December 31, 2026

Conditions

Uterine SarcomaVulvar CancerNon Epithelial Ovarian Cancers (NEOC)

Interventions

GENETIC

DNA, RNA, ctDNA, metabolomics

The use of specific assays or global molecular profiling to identify novel biomarkers based on DNA, RNA, protein, lipids, or metabolites obtained from tumor tissue or body fluids

Trial Locations (1)

Unknown

Fondazione Policlinico Gemelli IRCCS, Rome

All Listed Sponsors

lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT06582108 - UNDERSTANDING the RAREST GYNECOLOGICAL CANCERS: a MULTI -OMICS PLATFORM for IMPROVED PATIENTS MANAGEMENT | Biotech Hunter | Biotech Hunter